SpineThera is a biotechnology startup founded in 2012 and headquartered in Plymouth, Minnesota. The company specializes in creating innovative, sustained-release injectable medications aimed at treating pain. Their solutions provide patients and healthcare professionals with alternatives that enhance safety, improve treatment outcomes, and manage overall costs in markets with limited approved options. Recently, on 26 April 2022, SpineThera secured a significant $4.97M grant investment from the U.S. Department of Defense.
SpineThera operates in the Biotechnology, Health Care, Health and Wellness, and Pharmaceutical industries, demonstrating a broad scope and potential for impact. With a focus on sustained-release injectable medications, the company addresses a niche need in the market, aligning with the increasing demand for innovative pain management solutions.
This recent investment not only highlights the confidence of the U.S. Department of Defense in SpineThera's capabilities but also underscores the potential for the company's impact on the healthcare and biotechnology sectors. As an investor seeking opportunities in innovative healthcare solutions, SpineThera's groundbreaking approach and recent funding make it a compelling prospect for further consideration and monitoring.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $4.97M | 1 | U.S. Department of Defense | 26 Apr 2022 |
| Debt Financing | Unknown | - | 10 Dec 2021 | |
| Venture Round | $1.22M | - | 10 Dec 2021 | |
| Funding Round | $5.00M | - | 31 Mar 2019 | |
| Funding Round | $10.00M | - | 31 Dec 2018 |
No recent news or press coverage available for SpineThera.
We care about your data, and we'd love to use cookies make your experience better.
